EC Number | Application | Comment | Organism |
---|---|---|---|
3.5.4.B9 | medicine | APOBEC3G mediated checkpoint activation through checkpoint kinase 2 (Chk2) is one of the critical regulatory mechanisms that underlies the preferential DNA damage checkpoint response and radioresistance of Glioma Initiating Cells. Thus, anti-APOBEC3G therapy may synergize with radiotherapy and other current treatments to overcome the therapeutic resistance of gliomas. APOBEC3G represents a potential molecular target for novel therapeutics that will improve the treatment outcome of glioma patients | Homo sapiens |
3.5.4.38 | medicine | APOBEC3G mediated checkpoint activation through checkpoint kinase 2 (Chk2) is one of the critical regulatory mechanisms that underlies the preferential DNA damage checkpoint response and radioresistance of Glioma Initiating Cells. Thus, anti-APOBEC3G therapy may synergize with radiotherapy and other current treatments to overcome the therapeutic resistance of gliomas. APOBEC3G represents a potential molecular target for novel therapeutics that will improve the treatment outcome of glioma patients | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.5.4.B9 | Homo sapiens | Q9HC16 | - |
- |
3.5.4.38 | Homo sapiens | Q9HC16 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.5.4.B9 | mesenchymal glioma stem cell | APOBEC3G is preferentially expressed in mesenchymal gliomas | Homo sapiens | - |
3.5.4.38 | mesenchymal glioma stem cell | APOBEC3G is preferentially expressed in mesenchymal gliomas | Homo sapiens | - |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.5.4.B9 | APOBEC3G | - |
Homo sapiens |
3.5.4.38 | APOBEC3G | - |
Homo sapiens |